322TiP ENCEFALO (GEM2301) clinical trial: Encorafenib and binimetinib followed by cemiplimab and fianlimab in BRAF-mutant melanoma and symptomatic brain metastases

Patients (pts) with BRAF-mutant melanoma symptomatic brain metastases (MBM) have a high unmet medical need. Targeted therapy (TT) has shown high intracranial response rates (RR) in this population independent of the symptomatic status. Encorafenib (E) and binimetinib (B) showed an ORR over 60% in pts with symptomatic brain metastasis. However, the duration of responses with TT remains short-termed in most cases. Conversely, immunotherapy (IT) shows low RR but is capable of achieving long-term disease control, mostly in asymptomatic pts.

Authors

Institutions

Publication Details

Journal
Immuno-Oncology Technology
Published
2025-12-01
DOI
https://doi.org/10.1016/j.iotech.2025.101521
Primary Topic
Melanoma and MAPK Pathways
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

322TiP ENCEFALO (GEM2301) clinical trial: Encorafenib and binimetinib followed by cemiplimab and fianlimab in BRAF-mutant melanoma and symptomatic brain metastases

P. Cerezuela-Fuentes, G. Crespo, M. Quindós, I. Marquez-Rodas et al.
Immuno-Oncology Technology
Melanoma and MAPK Pathways
article

322TiP ENCEFALO (GEM2301) clinical trial: Encorafenib and binimetinib followed by cemiplimab and fianlimab in BRAF-mutant melanoma and symptomatic brain metastases

P. Cerezuela-Fuentes, G. Crespo, M. Quindós, I. Marquez-Rodas, A. Berrocal, L. Egaña, M. Gonzalez-Cao, M. Sotelo, J. Martin-Liberal, E. Muñoz-Couselo, L. Gutiérrez Sanz, P. Ayala de Miguel, A. Arance, M. Bringas, M.D.C. Alamo De La Gala, A. Soria, C. Aguado de la Rosa, E. Pérez-Ruiz, I. González-Barrallo
article en

Abstract

Patients (pts) with BRAF-mutant melanoma symptomatic brain metastases (MBM) have a high unmet medical need. Targeted therapy (TT) has shown high intracranial response rates (RR) in this population independent of the symptomatic status. Encorafenib (E) and binimetinib (B) showed an ORR over 60% in pts with symptomatic brain metastasis. However, the duration of responses with TT remains short-termed in most cases. Conversely, immunotherapy (IT) shows low RR but is capable of achieving long-term disease control, mostly in asymptomatic pts.

Immuno-Oncology TechnologyVol. 28
Hospital General Universitario Gregorio Marañón (ES), Hospital Clínico San Carlos (ES), Hospital Universitario Virgen Macarena (ES), Instituto Oncológico Dr. Rosell (ES), Marqués de Valdecilla University Hospital (ES), Biogipuzkoa Health Research Institute (ES), Hospital Universitario Puerta de Hierro Majadahonda (ES), Institut Català d'Oncologia (ES), Hospital San Pedro de Alcántara (ES), Hospital Clínic de Barcelona (ES), Hospital Universitario de Burgos (ES), Vall d'Hebron Hospital Universitari (ES), Hospital General Universitario De Valencia (ES), Donostiako Unibertsitate Ospitalea (ES), Instituto Murciano de Investigación Biosanitaria (ES), INCLIVA Health Research Institute (ES), Instituto de Investigación Biomédica de A Coruña (ES), Hospital Universitario Ramón y Cajal (ES), Instituto de Investigación Biomédica de Málaga (ES)
Good health and well-being
Openalex Percentile: Top 36%
Melanoma and MAPK Pathways
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.